Prostate-specific Antigen Promoter / Enhancer Driven Gene Therapy for Prostate Cancer : Construction and Testing of a Tissue-specific Adenovirus Vector 1

A range of luciferase reporter vectors was constructed, incorporating 5*-flanking sequences from the prostate-specific antigen (PSA), human glandular kallikrein 2 (hKLK2), and cytomegalovirus (CMV) promoters for expression control. Tissue specificity was evaluated in the PSA-positive line LNCaP and PSA-negative cells from different tissues of origin (CoLo320, DG75, EJ, A2780, and Jurkat). The minimal 628-bp PSA andhKLK2 promoters showed only low-level expression in either PSA-positive or PSA-negative cells and showed no increase with the addition of androgen. Tandem duplication of the PSA promoter slightly increased expression in PSA-positive LNCaP cells. The addition of CMV enhancer sequences upstream of a single PSA or hKLK2 promoter substantially but nonspecifically increased luciferase expression in all cell lines tested. However, placing a 1455-bp PSA enhancer sequence upstream of either the PSA or hKLK2 promoters increased expression 20-fold in the PSA-positive cell line LNCaP but not in the PSA-negative lines. Tandem duplication of the PSA enhancer increased expression to ;50-fold higher than either promoter alone while retaining tissue-specific control. The level of expression was reduced by the addition of a third copy of the PSA enhancer. Expression from all enhancer constructs was increased 100-fold above basal levels when induced with the androgen dihydrotestosterone, with the PSA-based constructs consistently exhibiting roughly twice the level of expression of thehKLK2-based constructs at all androgen concentrations. Adenovirus vectors were produced in which either enhanced green fluorescent protein or nitroreductase could be expressed from the optimized PSA double enhancer-promoter construct and evaluated in LNCaP cells and the bladder-derived line EJ. Control vectors with the CMV promoter gave good levels of expression in both cell lines, whereas the PSA constructs only produced detectable levels of protein in the LNCaP cells as assessed by fluorescence of enhanced green fluorescent protein or by Western blotting of nitroreductase. LNCaP but not EJ cells were selectively sensitized to the prodrug CB1954 following infection with Ad-PSAEEP-NR. The PSA-based nitroreductase virus produced comparable amounts of nitroreductase and sensitization to CB1954 approaching that of the CMV-driven virus. Plasmid and adenovirus constructs combining PSA enhancer and promoter sequences demonstrate selective expression of linked genes in PSApositive cells. The expression is induced by androgen and gives therapeutically relevant levels of effector proteins.

[1]  V. Mautner Methods for Growth and Purification of Enteric Adenovirus Type 40 , 1999 .

[2]  I. McNeish,et al.  Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954 , 1998, Gene Therapy.

[3]  G. Dranoff,et al.  Cancer gene therapy: connecting basic research with clinical inquiry. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Kerr,et al.  Adenoviral delivery of B7–1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells , 1998, Gene Therapy.

[5]  James M. Wilson,et al.  Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. , 1998, Human gene therapy.

[6]  R. Vile Gene therapy , 1998, Current Biology.

[7]  P. Opolon,et al.  Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. , 1997, The Journal of clinical investigation.

[8]  D. Kerr,et al.  Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. , 1997, Cancer gene therapy.

[9]  D. Tindall,et al.  Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. , 1997, Urology.

[10]  P. Opolon,et al.  Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. , 1996, Journal of the National Cancer Institute.

[11]  J. D. Miller,et al.  Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer (*) , 1996, The Journal of Biological Chemistry.

[12]  D. Tindall,et al.  Prostate‐specific human kallikrein (hK2) as a novel marker for prostate cancer , 1996, The Prostate. Supplement.

[13]  C. Tso,et al.  Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. , 1995, Human gene therapy.

[14]  Y. Soini,et al.  Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern‐blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies , 1993, International journal of cancer.

[15]  D. Tindall,et al.  Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. , 1993, Biochemistry.

[16]  D. Tindall,et al.  Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. , 1992, Biochemistry.

[17]  P. Riegman,et al.  The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. , 1991, Molecular endocrinology.

[18]  D. Tindall,et al.  Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. , 1991, Cancer research.

[19]  D. Tindall,et al.  In situ hybridization of prostate-specific antigen mRNA in human prostate. , 1990, The Journal of urology.

[20]  M. Digby,et al.  Human prostate specific antigen (PSA) gene: structure and linkage to the kallikrein-like gene, hGK-1. , 1989, Nucleic acids research.

[21]  P. Riegman,et al.  Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. , 1989, Biochemical and biophysical research communications.

[22]  A. Miller,et al.  Improved retroviral vectors for gene transfer and expression. , 1989, BioTechniques.

[23]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[24]  B. Morris,et al.  Primary structure of a human glandular kallikrein gene. , 1987, DNA.

[25]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .